Anaptysbio (ANAB) closed at $47.94 on October 21, 2026, up 5.5% from the previous close, on volume of 646,768 shares (30-day average 533,328).
Data as of October 21, 2026.
AnaptysBio quickly drops amid hearing on GSK/Tesaro contract breach
Seeking Alpha News (Tue, 20-Oct 3:49 PM ET)
Globe Newswire (Mon, 19-Oct 2:18 PM ET)
AnaptysBio gains as GSK granted FDA label expansion for Jemperli
Seeking Alpha News (Mon, 19-Oct 1:25 PM ET)
TipRanks (Mon, 19-Oct 12:25 PM ET)
Globe Newswire (Mon, 21-Sep 4:15 PM ET)
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Tue, 1-Sep 4:15 PM ET)
AnaptysBio’s $100 Million Stock Repurchase Plan Underscores Strong Cash Position and Strategic Shift
Market Chameleon (Fri, 21-Nov 3:56 AM ET)
Anaptys Sets Sights on Split: Biopharma and Royalty Businesses to Operate Independently by 2026
Market Chameleon (Tue, 30-Sep 6:31 AM ET)
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Anaptysbio trades on the NASDAQ stock market under the symbol ANAB.
As of October 21, 2026, ANAB stock price climbed to $47.94 with 646,768 million shares trading.
ANAB has a beta of 0.72, meaning it tends to be less sensitive to market movements. ANAB has a correlation of 0.01 to the broad based SPY ETF.
ANAB has a market cap of $1.43 billion. This is considered a Small Cap stock.
Last quarter Anaptysbio reported $27 million in Revenue and -$.11 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.35.
In the last 3 years, ANAB traded as high as $72.36 and as low as $6.11.
The top ETF exchange traded funds that ANAB belongs to (by Net Assets): VTI, XBI, IWM, VXF, IBB.
ANAB has outperformed the market in the last year with a price return of +171.8% while the SPY ETF gained +16.3%. However, in the short term, ANAB had mixed performance relative to the market. It has underperformed in the last 3 months, returning -4.7% vs +4.4% return in SPY. But in the last 2 weeks, ANAB shares have fared better than the market returning +0.1% compared to SPY -0.8%.
ANAB support price is $43.87 and resistance is $46.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANAB shares will trade within this expected range on the day.